

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Christof Westenfelder Confirmation No.: 6531  
SERIAL NUMBER: 10/551,317 EXAMINER: WEHBE, Anne Marie  
Sabrina  
FILING DATE: August 21, 2006 ART UNIT: 1633  
FOR: Stem-cell, precursor cell, or target cell-based treatment of multiorgan failure  
and renal dysfunction

**Mail Stop AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement ( 2 pages);
2. Modified Form PTO/SB/08(a) ( 4 pages); and
3. Copies of Cited References ( 2 Ref.).

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. **50-0311**, Reference No. **38447-201N01 US**.

Respectfully submitted,

/Sean M. Coughlin/

Ivor R. Elrifi, Reg. No. 39,529

Sean M. Coughlin, Reg. No. 48,593

Attorneys for Applicant

c/o MINTZ, LEVIN

Tel: (202) 585-3577

Fax: (617) 542-2241

**Customer No. 30623**

Dated: June 29, 2009

**E-filed**

**Date of Deposit: June 29, 2009**

**Attorney Docket No. 38447-201N01 US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT:	Christof Westenfelder	Confirmation No.:	6531
SERIAL NUMBER:	10/551,317	EXAMINER:	WEHBE, Anne Marie Sabrina
FILING DATE:	August 21, 2006	ART UNIT :	1633
FOR:	Stem-Cell, Precursor Cell, or Target Cell-Based Treatment of Multiorgan Failure and Renal Dysfunction		

**MAIL STOP AMENDMENT**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached PTO Form SB/08(a) in the above-identified application, copies of which are submitted herewith.

This Supplemental Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is believed to be required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO/SB/08a to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is

considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **38447-201N01US**.

Respectfully submitted,

/Sean M. Coughlin/  
Ivor R. Elrifi, Reg. No. 39,529  
Sean M. Coughlin, Reg. No. 48,593  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
Address all written correspondence to  
**Customer no.: 30623**  
Tel: (202) 585-3577  
Fax: (617) 542-2241

Date: June 29, 2009